纳米材料药物输送系统对炎症性肠病的分类
Haichen Wang1, Feifei Zhou2, Mengdan Shen1
1Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, 215002, People's Republic of China.
International journal of nanomedicine
|February 10, 2025
概括
纳米材料药物递送系统 (NDDS) 通过提高药物向性和疗效,为治疗炎症性肠病 (IBD) 提供了一个有前途的方法. 对于这些先进疗法的临床转化,需要进一步的研究.
科学领域:
- 胃肠病学 胃肠病学
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
背景情况:
- 炎症性肠病 (IBD),包括克罗恩氏病和性结肠炎,源于结肠壁缺陷,肠道失调和免疫失调.
- 目前IBD治疗面临的挑战包括药物溶解性差,不稳定性,无效向和显著的副作用.
- 由于IBD症状的慢性和反复性,传统疗法通常需要终身管理.
研究的目的:
- 审查纳米材料药物输送系统 (NDDS) 治疗IBD的分类和潜力.
- 突出NDDS如何克服传统IBD疗法的局限性.
- 探索NDDS物理化学特性对体内药理行为的影响和临床转化.
主要方法:
- 在IBD治疗中NDDS应用的文献综述.
- 对NDDS属性的分析,包括可溶性增强,生物可用性改善和有针对性的交付能力.
- 讨论在IBD中NDDS临床应用的挑战和未来方向.
主要成果:
- NDDS在优化药物分发,增强溶解性和生物可用性以及减少副作用方面显示出潜力.
- 这些系统可以改善药物的药理动力学,促进穿越障碍,并保护治疗剂免受降解.
- NDDS可以实现有针对性的输送,增加局部药物度和治疗疗效,同时最大限度地减少非目标效应.
结论:
- NDDS代表了IBD的有希望的治疗策略,提供了改善的药物输送和疗效.
- 尽管面临当前的挑战,NDDS可以有效地克服针对药物输送的生物障碍.
- 了解NDDS特性对于加速其临床转化和改善IBD患者的治疗结果至关重要.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:29Inflammatory Bowel Disease IV: Pharmacological Management
99
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
99
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
94
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
94
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
304
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
304